Pharmacotherapeutic options for overactive bladder (OAB) include antimuscarinics and the beta3-adrenoceptor agonist mirabegron.
Research and development of novel therapeutic options for OAB continues to be an active field. This review summarizes recent research with the existing therapies as well as the most promising agents in development.
Written by:
Andersson KE. Are you the author?
Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC.
Reference: Can Urol Assoc J. 2013 Sep;7(9-10 Suppl 4):S179-S180.
doi: 10.5489/cuaj.1617
PubMed Abstract
PMID: 24523838
UroToday.com Overactive Bladder (OAB) Section
